How Demand for Innovative Drugs is Skyrocketing the Revenues for Top 5 Huntingtons Disease Treatment Companies

Huntington’s Disease (HD) refers to a rare inherited disease in which the brain’s nerve cells begin degenerating with the passage of time. This progressive disorder does not have a definite cure. Some of the symptoms of this disease include depression, movement difficulties, involuntary jerking, mood swings, and others. The disease occurs in regions, including Europe and North America, providing a huge potential for companies for the launch of novel drugs. Moreover, technological aid and research grants are being offered by several government organizations and research institutes to boost the development of pipeline candidates.

The growth in the occurrence of the disease is poised to augment the market expansion. As per the Huntington’s Disease Society of America (HDSA), in 2021, 41,000 symptomatic Americans were reported, with over 200,000 people at risk of inheriting this disorder.

R&D initiatives by companies are increasingly taking place for the launch of novel therapeutic alternatives, which can help target the main disease symptoms. The change and reduction of Huntington's gene expression is one of the novel methods for the management or control of symptoms of this disease. For instance, SOM3355, which is a pipeline drug of SOM Biotech and a Vesicular Monoamine Transport inhibitor, works by interference with the way of movement of dopamine messages between neurons. Hence, R&D initiatives, such as gene therapy as well as precision medicines to treat the core symptoms of the condition can present lucrative opportunities for market growth.

The top 5 Huntington’s disease treatment solutions provider companies with substantial shares include Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries, Inc., Hikma Pharmaceuticals PLC, and Lupin. The shortage of approved products has resulted in the creation of an interest in companies to develop new drugs to cater to the clinical demand of the rising population of patients.

As per a report by Fortune Business Insights™, the market for Huntington’s disease treatment reached USD 1.14 billion in 2023 and is set to reach USD 3.06 billion by 2032 with a CAGR of 11.7%. The market is expected to reach a valuation of USD 1.26 billion in 2024. The market reflects a semi-consolidated market structure, with the presence of prominent players such as Teva Pharmaceutical Industries Ltd., and Neurocrine Biosciences, Inc.

Fortune Business Insights™ Profiles Top 5 Huntington’s Disease Treatment Provider Companies in the Market

1) Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. is the most prominent and dominant company in the marketaccounting for around a quarter of the market. It emphasizes over-the-counter and specialty products and generic medications. The Huntington’s disease treatment solutions provider has a robust product portfolio in the divisions, including respiratory, oncology, and central nervous system (CNS). It is directly present in Canada, Russia, Brazil, the U.K., Japan, the U.S., Israel, South Korea, and other nations. In 2023, the company registered a net sales worth USD 15.85 billion. In February 2023, the company secured the U.S. FDA approval for AUSTEDOXR (deutetrabenazine) extended-release tablets.

2) Sun Pharmaceutical Industries Ltd. 

Sun Pharmaceutical Industries Ltd. occupies the second-leading position, in the global market. It provides specialty generics and offers a varied portfolio of products for generic medications, active pharmaceutical ingredients, specialty medications, anti-retroviral medications, and over-the-counter (OTC) medications. Tetrabenazine’s branded and generic versions are also offered by the company for Huntington’s disease treatment. In 2023, the company witnessed a revenue worth USD 5.39 billion. Moreover, it has a robust direct presence in over 100 nations globally, with 43 manufacturing units spanning six continents. In January 2018, the Huntington’s disease treatment solutions provider made an agreement with Spain’s Health Research Institute of Santiago de Compostela and Israel’s Weizmann Institute of Science for the development of products to treat neurological disorders.

3) Dr. Reddy’s Laboratories Ltd. 

Dr. Reddy’s Laboratories Ltd. secures the third position in the global market. Its offerings include generics, biosimilars, branded generics, custom pharmaceutical services, differentiated formulations, and APIs. In 2023, the company witnessed revenue worth USD 2.98 billion. Some of the key therapeutic areas of the company include oncology, respiratory, pain management, cardiovascular, anti-infective, central nervous system (CNS), and gastrointestinal. Furthermore, the generic tetrabenazine version for Huntington’s disease treatment is offered by the company. It is operational in 74 nations and key markets in Russia, Europe, Brazil, India, and the U.S. In February 2018, the company announced the U.S. launch of generic tablets for Tetrabenazine. These tablets are meant to be used to treat involuntary movements related to Huntington’s disease.

4) Lupin 

Lupin captures the fourth largest market share in the top 5 Huntington’s disease treatment providers. It is one of the leading distributors and manufacturers of biotechnology products, over-the-counter products, and APIs. It carries out operations in different therapy areas such as respiratory, gastrointestinal, diabetes, cardiovascular, and anti-infective. In 2023, it witnessed revenue worth USD 2.02 billion and holds a robust geographical presence in over 100 nations globally, with seven research and development centers. In May 2022, the Huntington’s disease treatment solutions provider announced the resolution of the AUSTEDO (deutetrabenazine) patent dispute with Teva Pharmaceutical Industries Ltd. Through the settlement of this agreement, it will get the license for the sales of AUSTEDO from the start of April 2033.

5) Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. holds the fifth-leading position in the top 5 Huntington’s disease treatment providers. It is one of the prominent companies with the marketed product named INGREZZA. The solutions provider has an emphasis on the creation of advanced medicines for neuroendocrinology, neuropsychiatry-related disorders, and neurology. In 2023, the company’s revenue totaled USD 1.89 billion. It features a robust product pipeline for neurological disorders, including congenital adrenal hyperplasia, tardive dyskinesia, and chorea in Huntington’s disease, psychiatric disorders, epilepsy, and Parkinson’s disease. In September 2023, the company unveiled the New Drug Application for INGREZZA (valbenazine) oral granules.

Future Outlook for the Market

The disease cannot be cured; however, its progression can be managed. In this regard, beneficiary schemes, campaigns, and new programs are being actively launched by government authorities across the globe to educate patients regarding available Huntington’s disease treatment alternatives and surge awareness pertaining to this condition. These measures are slated to result in a rise in the number of cases of the diagnosis of the disorder, increasing the demand for innovative drugs.